55 results about "Fibromyalgia syndrome" patented technology

The present invention is directed to phenylaminopropanol derivatives of formulae I, II, and III: or a pharmaceutically acceptable salt thereof, compositions containing these derivatives, and methods of their use for the prevention and treatment of conditions ameliorated by monoamine reuptake including, inter alia, vasomotor symptoms (VMS), sexual dysfunction, gastrointestinal and genitourinary disorders, chronic fatigue syndrome, fibromyalgia syndrome, nervous system disorders, and combinations thereof, particularly those conditions selected from the group consisting of major depressive disorder, vasomotor symptoms, stress and urge urinary incontinence, fibromyalgia, pain, diabetic neuropathy, schizophrenia, and combinations thereof.

A method for treatment or prophylaxis of a disease state or other physiological condition, e.g., autism, delayed development, acid reflux disease, vaginal yeast infections, impaired hearing, chronic ear infections, seasonal allergies, Fibromyalgia syndrome, Crohn's disease, colitis, irritable bowel syndrome, interstitial cystitis, acne, sinusitis, rheumatoid arthritis, chronic fatigue syndrome, asthma, attention deficit disorder, attention deficit / hyperactivity disorder, rosacea, multiple sclerosis, hyperglycemia, or Ménière's disease, by administration of an anti-fungal composition that includes at least one of the bacilli (1) Bacillus subtilis, (2) Lactobacillus sporogenes, and (3) Streptococcus faecalis.

The present invention provides a method of treating fibromyalgia syndrome (FMS), chronic fatigue syndrome (CFS), and pain in an animal subject comprising administering a therapeutically effective amount of a dual serotonin norepinephrine reuptake inhibitor compound or a pharmaceutically acceptable salt thereof, wherein said dual serotonin norepinephrine reuptake inhibitor compound is characterized by a non-tricyclic structure and a greater inhibition of norepinephrine reuptake than serotonin reuptake, and wherein said compound is not administered adjunctively with phenylalanine or tyrosine. In particular, the use of milnacipran to treat FMS, CFS, and pain is disclosed.

Compositions and methods for alleviating the symptoms associated with chronic fatigue syndrome and fibromyalgia syndrome are provided. The compositions are based on use of a transdermal gel formulation delivery system for androgens, either alone or in combination with other hormones.

The present invention relates to a method of treating disorders including cognition impairment, generalized anxiety disorder, acute stress disorder, social phobia, simple phobias, pre-menstrual dysphoric disorder, social anxiety disorder, major depressive disorder, eating disorders, obesity, anorexia nervosa, bulimia nervosa, binge eating disorder, substance abuse disorders, chemical dependencies, nicotine addiction, cocaine addiction, alcohol addiction, amphetamine addiction, Lesch-Nyhan syndrome, neurodegenerative diseases, late luteal phase syndrome, narcolepsy, psychiatric symptoms anger, rejection sensitivity, movement disorders, extrapyramidal syndrome, Tic disorder, restless leg syndrome, tardive dyskinesia, sleep related eating disorder, night eating syndrome, stress urinary incontinence, migraine, neuropathic pain, diabetic neuropathy, fibromyalgia syndrome, chronic fatigue syndrome, sexual dysfunction, premature ejaculation, and male impotence. This method involves administering to a patient in need of such treatment a therapeutically effective amount of a disclosed compound. Such compounds are 4-phenyl substituted tetrahydroisoquinolines having the Formula IA, IB, IIA, IIB, IIIA or IIIC as set forth herein.

The invention is directed to a method of treating fibromyalgia syndrome in a subject, comprising administering a therapeutically effective amount of a carbamoyl compound, or pharmaceutically acceptable salt thereof.

The present invention relates to a pharmaceutical composition for treating, for example, a disorder or condition selected from the group consisting of hypertension, depression, generalized anxiety disorder, phobias, posttraumatic stress disorder, avoidant personality disorder, sexual dysfunction, eating disorders, obesity, chemical dependencies, cluster headache, migraine, pain, Alzheimer's disease, obsessive-compulsive disorder, panic disorder, memory disorders, Parkinson's diseases, endocrine disorders, cerebellar ataxia, gastrointestinal tract disorders, negative symptoms of schizophrenia, premenstrual syndrome, Fibromyalgia Syndrome, stress incontinence, Tourette syndrome, trichotillomania, kleptomania, male impotence, cancer, chronic paroxysmal hemicrania and headache in a mammal, preferably a human, comprising (i) an atypical antipsychotic or a pharmaceutically acceptable salt thereof, (ii) a 5-HT1B receptor antagonist or a pharmaceutically acceptable salt thereof, wherein the 5-HT1B receptor antagonist is selected from the group consisting of (A) a compound of the formula I as described in the specification and (B) a compound of the formula II as described in the specification, and optionally (iii) a pharmaceutically acceptable carrier.

Highly selective dual serotonin and norepinephrine reuptake inhibitors are provided. These compounds have a lower side-effect profile and are useful in compositions and products for use in treatment of a variety of conditions including depression, fibromyalgia, anxiety, panic disorder, agorophobia, post traumatic stress disorder, premenstrual dysphoric disorder, attention deficit disorder, obsessive compulsive disorder, social anxiety disorder, generalized anxiety disorder, autism, schizophrenia, obesity, anorexia nervosa, bulimia nervosa, Gilles de la Tourette Syndrome, vasomotor flushing, cocaine and alcohol addiction, sexual dysfunction, borderline personality disorder, fibromyalgia syndrome, diabetic neuropathic pain, chronic fatigue syndrome, pain, visceral pain, Shy Drager syndrome, Raynaud's syndrome, Parkinson's Disease, and epilepsy.

The present invention relates to methods and compositions comprising ribose and maleate for the treatment of fibromyalgia syndrome. The methods and compositions of the invention are especially useful for oral administration and are useful for alleviating the symptoms of pain, fatigue, and irritable bowel syndrome in fibromyalgia syndrome.

The present invention is directed to methods for providing long-term treatment of fibromyalgia syndrome (FMS) by administering a dual re-uptake inhibitor to a patient with FMS. More particularly, the present invention is directed to the long-term treatment of FMS by administering a norepinephrine-serotonin reuptake inhibitor (NSRI) to a patient with FMS.

Methods for treating fatigue associated with fibromyalgia by administering high-dose milnacipran to a patient suffering from such fatigue are provided. Also provided are methods for the long-term treatment of fatigue associated with FMS by administering milnacipran to a patient suffering from such fatigue.

The present invention provides a method of treating fibromyalgia syndrome (FMS), chronic fatigue syndrome (CFS), and pain in an animal subject. The method generally involves administering a therapeutically effective amount of a dual serotonin norepinephrine reuptake inhibitor compound or a pharmaceutically acceptable salt thereof, wherein said dual serotonin norepinephrine reuptake inhibitor compound is characterized by a non-tricyclic structure and an equal or greater inhibition of norepinephrine reuptake than serotonin reuptake. In particular, the use of milnacipran to treat FMS, CFS, and pain is disclosed.

Compositions and methods for alleviating the symptoms associated with chronic fatigue syndrome and fibromyalgia syndrome are provided. The compositions are based on use of a transdermal gel formulation delivery system for androgens, either alone or in combination with other hormones.

The present invention provides a method of treating fibromyalgia syndrome (FMS), chronic fatigue syndrome (CFS), and pain in an animal subject comprising administering a therapeutically effective amount of a dual serotonin norepinephrine reuptake inhibitor compound or a pharmaceutically acceptable salt thereof, wherein said dual serotonin norepinephrine reuptake inhibitor compound is characterized by a non-tricyclic structure and a greater inhibition of norepinephrine reuptake than serotonin reuptake, and wherein said compound is not administered adjunctively with phenylalanine or tyrosine. In particular, the use of milnacipran to treat FMS, CFS, and pain is disclosed.

Selective dual serotonin and norepinephrine reuptake inhibitors are provided. These compounds have a lower side-effect profile and are useful in compositions and products for use in treatment of a variety of conditions including depression, fibromyalgia, anxiety, panic disorder, agoraphobia, post traumatic stress disorder, premenstrual dysphoric disorder, attention deficit disorder, obsessive compulsive disorder, social anxiety disorder, generalized anxiety disorder, autism, schizophrenia, obesity, anorexia nervosa, bulimia nervosa, Gilles de la Tourette Syndrome, vasomotor flushing, cocaine and alcohol addiction, sexual dysfunction, borderline personality disorder, fibromyalgia syndrome, diabetic neuropathic pain, chronic fatigue syndrome, pain, Shy Drager syndrome, Raynaud's syndrome, Parkinson's Disease, and epilepsy.

Methods for improving physical function in fibromyalgia syndrome by administering an NSRI such as milnacipran as disclosed.

Provided are a sustained-release composition including pregabalin and a pharmaceutically acceptable salt thereof using a gastroretentive drug delivery system (GRDDS), an oral sustained-release formulation using the composition, and a preparation method thereof. In a sustained-release composition according to the present invention and a formulation including the same, a coating compartment including a sugar or a derivative thereof and a plasticizer is introduced onto the outer surface of pregabalin having a less stable structure to ensure stability and to improve compatibility with excipients at the same time, and also to effectively control the release rate. As a result, dosing convenience is improved to provide a gastroretentive drug delivery system having enhanced patient compliance. Therefore, the present invention may exhibit improved therapeutic or prophylactic effects on various neurological diseases, such as neuropathic pain, epilepsy, fibromyalgia syndrome, etc., which have not been easily accomplished due to the characteristics of pregabalin.

The present invention provides a method for treating certain rheumatic conditions such as fibromyalgia syndrome, chronic fatigue syndrome, myofascial pain syndrome, and Gulf War syndrome, among others, by administration of trimetazadine, along with related compositions and kits.

The present invention provides a method for treating certain rheumatic conditions such as fibromyalgia syndrome, chronic fatigue syndrome, myofascial pain syndrome, and Gulf War syndrome, among others, by administration of trimetazidine, along with related compositions and kits.

The invention discloses traditional Chinese medicine pills for treating fibromyalgia syndrome and a preparing method of the traditional Chinese medicine pills and belongs to the field of traditional Chinese medicine. The effectively ingredients of the traditional Chinese medicine pills comprise cissus pteroclada hayata, cassia twigs, bauhinia championii, astragalus membranaceus, cynanchum wilfordii, rhizoma atractylodis macrocephalae, cortex albiziae, angelica sinensis, lycopodium clavatum, radix paeoniae alba, tuber fleeceflower stems, radix curcumae, boston ivy, rhizoma cyperi, caulophyllum robustum, radix bupleuri, ainsliaea pertyoides, ephedra, gaultheria yunnanensis, pittosporum roots, hairy ficus formosana roots, cortex acanthopanacis, liquorice and alangium platanifolium roots. The medicine pills are applied according to symptoms of diseases and have the effects of tonifying the liver and kidney, invigorating spleen and supplementing qi, soothing liver-qi stagnation, nourishing the blood for tranquilization, dispelling wind and eliminating dampness, clearing and activating the channels and collaterals, invigorating the circulation of scattered stasis and promoting qi circulation to relieve pain. The absorption effect is good, the curative effect is remarkable, no toxic and side effect and clinical adverse reactions exist, and it is proved by clinical experiments that the traditional Chinese medicine pills are higher in the cure rate of the fibromyalgia syndrome and have very good clinical application and popularization value and prospects.

Selective dual serotonin and norepinephrine reuptake inhibitors are provided. These compounds have a lower side-effect profile and are useful in compositions and products for use in treatment of a variety of conditions including depression, fibromyalgia, anxiety, panic disorder, agorophobia, post traumatic stress disorder, premenstrual dysphoric disorder, attention deficit disorder, obsessive compulsive disorder, social anxiety disorder, generalized anxiety disorder, autism, schizophrenia, obesity, anorexia nervosa, bulimia nervosa, Gilles de la Tourette Syndrome, vasomotor flushing, cocaine and alcohol addiction, sexual dysfunction, borderline personality disorder, fibromyalgia syndrome, diabetic neuropathic pain, chronic fatigue syndrome, pain, Shy Drager syndrome, Raynaud's syndrome, Parkinson's Disease, and epilepsy.

The invention discloses an orally-taken traditional Chinese medicine composition for treating fibromyalgia syndrome. The traditional Chinese medicine composition is prepared from the following material medicines: herba epimedii, rhizoma curculiginis, prepared rehmannia root, eclipta, obscured homalomena rhizome, pyrola, radix curcuma, rhizoma drynariae, corydalis amabilis, rhizoma smilacis glabrae, liquidambar formosana hance and long-noded pit viper. Compared with the common antidepressant, muscle relaxant, anticonvulsive drugs, and the like, the orally-taken traditional Chinese medicine composition for treating fibromyalgia syndrome has the advantages of positive curative effect, small side effect, high compliance of a patient and the like.

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine for treating fibromyalgia syndrome. The traditional Chinese medicine is prepared from the following raw materials by weight: 10-30g of six-eared blumea, 10-20g of evergreen mucuna root and leaf, 40-60g of loofah sponge, 30-40g of Japanese snailseed root, 20-50g of licorice root, 20-30g of lycopodiella inundata, 10-20g of ficus pumila, 10-30g of smilax china, 20-40g of gentiana macrophylla, 20-40g of berba aristolochiae mollissimae, 10-30g of radix angelicae pubescentis, 10-30g of morinda officinalis, 20-40g of bidens bipinnata, 10-40g of angelica sinensis, 10-20g of curious kadsura root stem, 10-40g of radix zanthoxyli and 10-30g of scandent schefflera stem and leaf. All the raw materials of the traditional Chinese medicine are matched to play the effects of clearing and activating the channels and collaterals, dispelling wind, eliminating dampness, activating blood circulation to remove stasis, and promoting qi circulation to relieve pain. When used for treating fibromyalgia syndrome, the traditional Chinese medicine has the advantages of exact and remarkable curative effect, high effective rate, and no toxic or side effect; in addition, the traditional Chinese medicine can avoid the relapse of fibromyalgia syndrome after curing the fibromyalgia syndrome.

The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of autonomic and other neurological disorders may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of neurogenic orthostatic hypotension (NOH), as well as NOH associated with multiple system atrophy (MSA), familial amyloid polyneuropathy (FAP), pure autonomic failure (PAF), and Parkinson's disease (PD), intradialytic hypotension (IDH) or hemodialysis-induced hypotension, hypotension associated with fibromyalgia syndrome (FMS) and chronic fatigue syndrome (CFS).

The invention discloses a tradtional Chinese medicine composition for treating female fibromyalgia syndromes. The tradtional Chinese medicine composition is prepared from the following raw materials: fructus broussonetiae, mulberry, tortoise shell, dogwood, cortex cinnamomi, fructus citri, flos rosae rugosae, tribulus terrestris, valerian, nacre mother of pearl, platycodon grandiflorum, fevervine, rhizoma gastrodiae, herba aristolochiae and tamarix chinensis. The tradtional Chinese medicine composition for treating female fibromyalgia syndromes correspond with the female physiological characteristics; compared with the frequently-used antidepressant, muscle relaxant and anticonvulsant, the pharmaceutical composition has the advantages of being definite in curative effect, small in side effect and high in patient compliance; and therefore, the tradtional Chinese medicine composition is a dedicated drug for treating female fibromyalgia syndromes.

The purpose of the present invention is to provide a compound that exerts a strong analgesic action against on pain, in particular, against neuropathic pain and / or fibromyalgia syndrome. The present invention provides a cyclic amine derivative represented by chemical formula (AA), a prodrug thereof or a pharmaceutically acceptable salt thereof.

The present invention provides for the use of a heterocyclic amine-type compound to prepare a medicament for the treatment of symptoms of fibromyalgia syndrome, or chronic fatigue syndrome.